查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595133

膀胱过动症治疗市场：依药物治疗、疾病类型、分布划分 - 全球预测 2025-2030

Overactive Bladder Treatment Market by Drug Therapy (Anticholinergic, BOTO, Darifenacin), Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

膀胱过动症治疗市场2023年估值为45.4亿美元，预计到2024年将达到47.1亿美元，复合年增长率为3.74%，预计到2030年将达到58.8亿美元。

膀胱过动症(OAB) 治疗市场针对全球个人，重点在于旨在控制尿急、频尿和尿失禁等症状的产品和治疗解决方案。由于人口老化和膀胱疾病盛行率的增加，需要有效的膀胱过动症治疗，并且需要药物和非药物治疗来改善患者的生活品质。应用范围从口服药物和膀胱内治疗到先进的神经调节剂和行为干预，最终用户包括医院、泌尿系统诊所和居家医疗机构。市场成长受到药物配方进步、医疗保健支出增加以及意识和诊断率提高等因素的影响。药物和医疗设备的技术进步提供了宝贵的机会，特别是在开发靶向生技药品和微创治疗方面，而製药公司和研究机构之间的合作不断加强，有助于培育创新解决方案。挑战包括新治疗方法的高成本、监管障碍以及发展中地区的意识低下，这些都可能限製成长潜力。现有治疗方法的安全问题和副作用使患者的依从性和采用更加复杂。策略建议包括投资研究和开发，以提高现有治疗方法的有效性并减少副作用。鼓励公司专注于以患者为中心的创新和数数位化，以优化治疗计划。例子包括部署人工智慧和机器学习来进行病患监测和个人化治疗调整。创新还可以集中于将生活方式介入与药物治疗相结合的组合方法，以实现全人管理。随着需求的成长，透过策略伙伴关係和高效的供应链框架，新兴市场存在着巨大的扩张空间。 OAB 治疗市场仍然充满活力，一直朝着创新、经济高效且易于使用的解决方案发展，这对于维持成长和加强患者照护至关重要。

主要市场统计
基准年[2023] 45.4亿美元
预测年份 [2024] 47.1亿美元
预测年份 [2030] 58.8亿美元
复合年增长率（%） 3.74%

市场动态：揭示快速发展的膀胱过动症治疗市场的关键市场洞察

膀胱过动症治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 患有膀胱过动症(OAB) 症状的人数增加
    • 人口老化加剧
  • 市场限制因素
    • 膀胱过动症治疗相关的副作用和风险
  • 市场机会
    • 膀胱过动症临床研究试验和管道
  • 市场挑战
    • 对膀胱过动症认识不足

波特五力：驾驭膀胱过动症治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解膀胱过动症治疗市场的外在影响

外部宏观环境因素在塑造膀胱过动症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解膀胱过动症治疗市场的竞争格局

膀胱过动症治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵膀胱过动症治疗市场供应商的绩效评估

FPNV定位矩阵是评估膀胱过动症治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了膀胱过动症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对膀胱过动症治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 患有膀胱过动症(OAB) 症状的人数不断增加
      • 人口老化加剧
    • 抑制因素
      • 膀胱过动症治疗相关的副作用和风险
    • 机会
      • 膀胱过动症临床研究试验和管道
    • 任务
      • 对 OAB 状况认识的局限性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章药物治疗膀胱过动症症市场

  • 抗胆碱能药
  • 波托
  • 达非那新
  • 非索罗定
  • Mirabegron
  • 神经刺激
  • 奥昔布宁
  • 索利那新

第七章膀胱过动症治疗市场：依疾病类型

  • 特发性膀胱过动症
  • 神经源性膀胱过动症

第八章膀胱过动症症治疗市场经销商

  • 医院和医院药房
  • 网路药房
  • 零售药房

第九章北美和南美膀胱过动症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区膀胱过动症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲膀胱过动症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Allergan plc
  • Astellas Pharma Inc.
  • Cipla Limited
  • DETROL LA by Viatris Company
  • Endo International plc
  • Granules India Limited
  • Hisamitsu Pharmaceutical Co., Inc.
  • Medtronic plc
  • Mylan NV
  • Pfizer Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Urovant Sciences Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-036C5CF3B4ED

The Overactive Bladder Treatment Market was valued at USD 4.54 billion in 2023, expected to reach USD 4.71 billion in 2024, and is projected to grow at a CAGR of 3.74%, to USD 5.88 billion by 2030.

The overactive bladder (OAB) treatment market focuses on products and therapeutic solutions designed to manage symptoms such as urinary urgency, frequency, and incontinence affecting individuals worldwide. The necessity for effective OAB treatments arises from a growing aging population and increased prevalence of bladder disorders, which necessitates ongoing innovation in pharmacological and non-pharmacological therapies to improve patient quality of life. Applications extend from oral medications and intravesical therapies to advanced neuromodulation devices and behavioral interventions, with end-users encompassing hospitals, urological clinics, and home healthcare settings. Market growth is influenced by factors such as advancements in drug formulations, increasing healthcare expenditure, and heightened awareness and diagnosis rates. Technological advancements in pharmaceuticals and medical devices present valuable opportunities, particularly in the development of targeted biologics and minimally invasive treatments, while increasing collaborations between pharmaceutical companies and research institutions can aid in fostering innovative solutions. Challenges include high costs associated with new treatment modalities, regulatory hurdles, and limited awareness in developing regions, which may constrain growth potential. Safety concerns and side effects of existing treatment options further complicate patient compliance and adoption. Strategic recommendations involve investing in R&D to enhance the efficacy and reduce side effects of existing treatments. Companies are encouraged to focus on patient-centric innovations and digitization to optimize treatment plans; for instance, deploying AI and machine learning for patient monitoring and personalized therapy adjustments. Innovation could also focus on combinatory approaches that integrate lifestyle interventions with pharmacotherapy for holistic management. With growing demand, there is significant room for expansion in emerging markets through strategic partnerships and efficient supply chain frameworks. The OAB treatment market remains dynamic, with a strong trajectory toward innovative, cost-effective, and accessible solutions crucial for sustaining growth and enhancing patient care.

KEY MARKET STATISTICS
Base Year [2023] USD 4.54 billion
Estimated Year [2024] USD 4.71 billion
Forecast Year [2030] USD 5.88 billion
CAGR (%) 3.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Overactive Bladder Treatment Market

The Overactive Bladder Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growth in number of people with overactive bladder (OAB) symptoms
    • Increase in aging population
  • Market Restraints
    • Adverse effects and risk associated with overactive bladder treatment
  • Market Opportunities
    • Overactive bladder clinical research trials and pipeline
  • Market Challenges
    • Limited awareness of OAB condition

Porter's Five Forces: A Strategic Tool for Navigating the Overactive Bladder Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Overactive Bladder Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Overactive Bladder Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Overactive Bladder Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Overactive Bladder Treatment Market

A detailed market share analysis in the Overactive Bladder Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Overactive Bladder Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Overactive Bladder Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Overactive Bladder Treatment Market

A strategic analysis of the Overactive Bladder Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Overactive Bladder Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Astellas Pharma Inc., Cipla Limited, DETROL LA by Viatris Company, Endo International plc, Granules India Limited, Hisamitsu Pharmaceutical Co., Inc., Medtronic plc, Mylan N.V., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Urovant Sciences Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Overactive Bladder Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Therapy, market is studied across Anticholinergic, BOTO, Darifenacin, Fesoterodine, Mirabegron, Neurostimulation, Oxybutynin, and Solifenacin.
  • Based on Disease Type, market is studied across Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity.
  • Based on Distribution, market is studied across Hospital & Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growth in number of people with overactive bladder (OAB) symptoms
      • 5.1.1.2. Increase in aging population
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects and risk associated with overactive bladder treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Overactive bladder clinical research trials and pipeline
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness of OAB condition
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Overactive Bladder Treatment Market, by Drug Therapy

  • 6.1. Introduction
  • 6.2. Anticholinergic
  • 6.3. BOTO
  • 6.4. Darifenacin
  • 6.5. Fesoterodine
  • 6.6. Mirabegron
  • 6.7. Neurostimulation
  • 6.8. Oxybutynin
  • 6.9. Solifenacin

7. Overactive Bladder Treatment Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Idiopathic Bladder Overactivity
  • 7.3. Neurogenic Bladder Overactivity

8. Overactive Bladder Treatment Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital & Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Overactive Bladder Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Overactive Bladder Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Overactive Bladder Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Astellas Pharma Inc.
  • 4. Cipla Limited
  • 5. DETROL LA by Viatris Company
  • 6. Endo International plc
  • 7. Granules India Limited
  • 8. Hisamitsu Pharmaceutical Co., Inc.
  • 9. Medtronic plc
  • 10. Mylan N.V.
  • 11. Pfizer Inc.
  • 12. Sunovion Pharmaceuticals Inc.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Urovant Sciences Inc.
  • 15. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. OVERACTIVE BLADDER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OVERACTIVE BLADDER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DARIFENACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY FESOTERODINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MIRABEGRON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY OXYBUTYNIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SOLIFENACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IDIOPATHIC BLADDER OVERACTIVITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROGENIC BLADDER OVERACTIVITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY HOSPITAL & HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 150. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023